1. Introduction

Royalty structures for genetic inventions refer to the legal and financial arrangements through which inventors, biotechnology companies, universities, research institutions, and patent holders receive compensation for the authorised use, licensing, commercialisation, or exploitation of genetic technologies.

Genetic inventions include:

Genetically modified organisms (GMOs).

Isolated and modified DNA sequences.

Gene-editing technologies, including CRISPR-Cas systems.

Recombinant DNA technologies.

Synthetic genes and genetic constructs.

Gene therapies and genetic medicines.

Diagnostic genetic testing methods.

Genetically modified agricultural seeds.

Engineered microorganisms and biological production systems.

Royalty arrangements are particularly important because genetic inventions frequently involve multiple contributors. A single commercial biotechnology product may depend on an original gene discovery, a patented vector, a gene-editing technique, laboratory processes, and downstream pharmaceutical or agricultural applications.

Consequently, royalty law must balance three competing interests:

Protecting the economic rights of inventors and patent holders.

Ensuring reasonable access to essential genetic technologies.

Preventing excessive licensing charges and monopolistic exploitation.

In India, royalty structures are governed principally by the Patents Act, 1970, contractual licensing principles, competition law, and relevant biotechnology regulatory frameworks.

2. Legal Nature of Royalties in Genetic Inventions

A royalty is a payment made by a licensee to a patent owner or technology rights holder in exchange for permission to use protected intellectual property.

A genetic invention may generate royalties through several legal mechanisms.

A. Patent licensing royalties

A patent holder permits another organisation to manufacture, use, sell, or commercially exploit a patented genetic invention in exchange for payment.

B. Research and development royalties

Research institutions may receive compensation when genetic inventions developed through publicly funded or collaborative research are commercially exploited.

C. Agricultural biotechnology royalties

Companies licensing genetically modified seeds or genetic traits may charge technology fees or royalties to seed manufacturers and other authorised users.

D. Pharmaceutical biotechnology royalties

Patented gene therapies, recombinant proteins, biologics, and genetic diagnostic technologies may generate royalties through manufacturing and commercialisation agreements.

E. Cross-licensing royalties

Two biotechnology companies may exchange patent rights. Where the value of the licensed portfolios differs, one party may pay balancing royalties to the other.

3. Major Types of Royalty Structures

A. Fixed royalty structure

Under this arrangement, the licensee pays a predetermined amount for each unit of genetic technology used or commercialised.

For example, a seed manufacturer may pay a fixed royalty for every packet of genetically modified seeds sold.

Advantages:

Predictable revenue.

Simple accounting.

Easier enforcement of contractual obligations.

Disadvantages:

May not reflect the actual commercial value of the invention.

Can impose disproportionate burdens on smaller manufacturers.

B. Percentage-based royalty

The licensee pays a predetermined percentage of revenue generated through commercial exploitation.

For example, a pharmaceutical company licensing a patented gene therapy may agree to pay 5% of net sales to the patent holder.

The royalty calculation must clarify:

Gross sales or net sales.

Permitted deductions.

Returns and rebates.

Distribution expenses.

Territory-specific sales.

Currency conversion.

Audit rights.

C. Milestone-based royalty

Payments are triggered when specific research or commercial milestones are achieved.

Examples include:

Successful laboratory validation.

Completion of preclinical testing.

Clinical-trial approval.

Regulatory marketing authorisation.

First commercial sale.

This arrangement is particularly useful in gene therapy and biotechnology research because commercial success is uncertain.

D. Tiered royalty structure

Royalty percentages increase or decrease depending on sales volume or commercial performance.

For instance:

These figures are illustrative contractual terms, not statutory rates.

E. Sublicensing royalty

A licensee may receive permission to sublicense genetic technology to another biotechnology company.

The original patent owner may receive a percentage of sublicensing revenue.

Such agreements must specify whether the royalty applies to:

Upfront sublicensing payments.

Milestone payments.

Running royalties.

Technology-transfer fees.

F. Compulsory licensing and regulated royalties

Compulsory licensing allows certain parties to use patented inventions without the patent holder's voluntary consent, subject to statutory requirements.

Under Section 84 of the Indian Patents Act, 1970, compulsory licences may be granted when statutory conditions are satisfied, including failure to meet reasonable public requirements, lack of reasonable affordability, or non-working of the patent in India.

The Controller may determine the terms and conditions, including the royalty payable to the patent holder.

This is particularly important where genetic medicines or biotechnology products are essential to public health.

4. Important Indian Legal Provisions

A. Patents Act, 1970

The following provisions are particularly relevant.

An important distinction is that a genetic sequence discovered in nature is not automatically patentable merely because it has commercial value. A qualifying technical invention must satisfy the applicable patentability requirements.

Sections 83 and 90 are particularly important because they prevent patent licensing from being treated as an unrestricted entitlement to impose any royalty whatsoever.

Government of India+3

B. Competition Act, 2002

Royalty agreements involving genetic inventions may also attract competition law.

Relevant provisions include:

Section 3: Anti-competitive agreements.

Section 4: Abuse of dominant position.

Section 19: Investigation of anti-competitive conduct.

Section 27: Orders and penalties for violations.

A biotechnology company possessing essential genetic technology may face competition-law scrutiny if it imposes unfair licensing conditions, discriminatory royalties, or restrictions that substantially harm competition.

However, the mere existence of a high royalty does not automatically establish an infringement of competition law. Market dominance, the nature of the agreement, its effects and applicable statutory exceptions must be examined.

C. Biological Diversity Act, 2002

Access to biological resources and associated traditional knowledge may generate additional benefit-sharing obligations.

The biological diversity framework is relevant when genetic inventions are developed using biological resources obtained from India.

Important considerations include:

Access to biological resources.

Benefit-sharing arrangements.

Rights of local communities.

Commercial utilisation.

Intellectual property applications involving biological resources.

Benefit-sharing payments and patent royalties are legally distinct. A company may have contractual royalty obligations to a patent owner and separate statutory benefit-sharing obligations under applicable biodiversity law.

The amended Biological Diversity Act, 2023 and the applicable rules and regulations must be considered when determining the relevant access and benefit-sharing requirements.

5. Important Case Laws

The following judgments establish important principles concerning patent ownership, genetic technologies, licensing, reproduction of patented biological materials and royalty-related disputes.

Case 1: Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019)

SUPREME COURT OF INDIA · 8 JANUARY 2019

Citation: (2019) 3 SCC 381.

Facts:

Monsanto developed biotechnology involving Bacillus thuringiensis (Bt) genetic material used to produce insect-resistant cotton.

Monsanto licensed its technology to Indian seed companies, including Nuziveedu Seeds Ltd., under licensing arrangements involving technology fees and royalty payments.

A dispute developed concerning the patentability of the genetic technology, licensing arrangements and the regulatory framework applicable to genetically modified seeds.

Legal issues:

Whether the claimed genetic technology qualified for patent protection.

Whether the patentability restrictions under Section 3(j) applied.

Whether the dispute could properly be resolved through summary proceedings.

Whether the licensing arrangements were legally enforceable.

Judgment:

The Supreme Court set aside the Delhi High Court's summary judgment and remitted the matter for adjudication on the merits.

The Court emphasised that the complicated scientific and legal questions concerning patent validity required proper examination rather than summary determination.

Importance for royalty structures:

The case is significant because it demonstrates that biotechnology royalties depend upon the legal validity and enforceability of the underlying intellectual property.

A royalty agreement cannot automatically establish that the underlying genetic technology is patentable.

The judgment also highlights the importance of distinguishing between:

Patent rights over genetic constructs.

Rights concerning seeds and plant varieties.

Contractual technology fees.

Regulatory price-control arrangements.

The Supreme Court did not establish a universal royalty percentage or finally determine the merits of the patent-validity dispute.

Sci API+2

Case 2: Bayer Corporation v. Union of India (2014)

SUPREME COURT OF INDIA · COMPULSORY LICENSING

Citation: (2014) 6 SCC 330.

Facts:

The dispute concerned Bayer's patented cancer medicine Nexavar and the compulsory licence granted to Natco Pharma.

Natco sought permission to manufacture and sell a more affordable generic version of the patented medicine.

Legal issue:

Whether the statutory conditions for granting a compulsory licence under Section 84 were satisfied.

Judgment:

The Supreme Court declined to interfere with the compulsory licensing outcome.

The case reinforced the significance of public affordability, reasonable public requirements and working of patents in India.

Importance for genetic inventions:

Although the invention was pharmaceutical rather than genetic, the decision is relevant to patented gene therapies, biologics and other expensive biotechnology products.

It demonstrates that patent exclusivity must operate alongside public-interest obligations.

Royalty payments under compulsory licences must reflect the statutory requirements rather than simply reproduce the commercial terms demanded by the patent owner.

Case 3: Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

UNITED STATES SUPREME COURT · 13 JUNE 2013

Citation: 569 U.S. 576 (2013).

Facts:

Myriad Genetics identified the location and sequence of BRCA1 and BRCA2 genes associated with increased risks of breast and ovarian cancer.

It obtained patents relating to these genes and exercised control over certain genetic testing activities.

The patents generated controversy concerning access to genetic testing and the commercial control of naturally occurring DNA.

Legal issue:

Whether naturally occurring DNA sequences could be patented merely because they had been isolated from the human body.

Judgment:

The United States Supreme Court held that naturally occurring DNA is not patent eligible merely because it has been isolated.

However, complementary DNA (cDNA) may be patent eligible in circumstances where it is not naturally occurring, subject to the applicable patentability requirements.

Importance for royalty structures:

The decision is fundamental to genetic patent licensing.

It restricts royalty claims based solely on the discovery and isolation of naturally occurring human genetic sequences.

It also illustrates the distinction between:

Naturally occurring genetic information.

Technically modified genetic material.

Artificially constructed genetic products.

Patentable diagnostic or laboratory processes.

A biotechnology company cannot justify exclusive royalty demands merely by claiming ownership of a naturally occurring human gene.

Government of India

Case 4: Bowman v. Monsanto Co. (2013)

UNITED STATES SUPREME COURT · 13 MAY 2013

Citation: 569 U.S. 278 (2013).

Facts:

Vernon Bowman purchased Monsanto's patented herbicide-resistant soybean seeds.

He planted the seeds, harvested the resulting crop and replanted harvested seeds to produce additional generations.

Monsanto argued that this reproduction infringed its patent rights.

Judgment:

The Supreme Court held that patent exhaustion resulting from an authorised sale does not give a purchaser unrestricted permission to reproduce patented seeds.

The purchaser may use or resell the particular patented article, but cannot automatically reproduce new copies of the patented invention.

Importance for royalty structures:

This case is especially relevant to agricultural biotechnology.

It establishes an important distinction between:

Royalty obligations associated with authorised seed licensing.

Rights acquired through an authorised sale.

Reproduction of patented genetic material.

Patent exhaustion.

It demonstrates why biotechnology licences must clearly define seed-saving, replanting, reproduction and commercial propagation rights.

LII / Legal Information Institute

Case 5: Diamond v. Chakrabarty (1980)

UNITED STATES SUPREME COURT · 16 JUNE 1980

Citation: 447 U.S. 303 (1980).

Facts:

Ananda Chakrabarty developed a genetically engineered bacterium capable of breaking down multiple components of crude oil.

The invention involved combining genetic characteristics to create a microorganism with a new functional capability.

Legal issue:

Whether a genetically engineered living microorganism could qualify as patentable subject matter.

Judgment:

The United States Supreme Court held that a genetically engineered microorganism created by human intervention could qualify as patentable subject matter.

The Court distinguished human-made inventions from naturally occurring products of nature.

Importance for royalty structures:

This case provides an important foundation for commercial licensing of genetically engineered microorganisms.

It supports the possibility of patent protection for qualifying engineered biological inventions, thereby enabling licensing and royalty arrangements.

However, patent eligibility does not automatically establish entitlement to every claimed royalty. Novelty, non-obviousness, disclosure and other patent requirements must also be satisfied.

Case 6: Monsanto Canada Inc. v. Schmeiser (2004)

SUPREME COURT OF CANADA · 21 MAY 2004

Citation: [2004] 1 SCR 902.

Facts:

Percy Schmeiser, a Canadian farmer, was found to have cultivated canola containing Monsanto's patented Roundup Ready genetic technology.

Monsanto brought an infringement action.

Schmeiser argued that he had not intentionally purchased the patented seeds or obtained a licence.

Legal issue:

Whether cultivating plants containing patented genetic technology could constitute patent infringement.

Judgment:

The Supreme Court of Canada found patent infringement because Schmeiser's activities involved the commercial exploitation of the patented genetic invention.

However, it did not award Monsanto profits because the evidence did not establish that Schmeiser had obtained an economic advantage attributable to the patented technology.

Importance for royalty structures:

The case is significant for understanding the relationship between patent infringement, commercial exploitation and financial compensation.

It demonstrates that:

Patent infringement and royalty liability are not necessarily identical.

Economic benefit may be relevant when determining an account of profits.

Genetic technology licences should specify permitted agricultural uses.

Farmers' rights and patent holders' rights must be evaluated under the applicable legislation.

The decision is particularly important for genetically modified crops and agricultural biotechnology licensing.

6. Factors Determining the Amount of Genetic-Invention Royalties

Royalty rates are not determined by one universal statutory formula. They are generally negotiated according to the commercial and technical value of the invention, subject to applicable legal restrictions.

The following factors are particularly relevant.

7. Royalty Structures in Different Biotechnology Sectors

A. Agricultural genetic inventions

Triple-gene Transgenic Cotton Exhibits Tolerance Against Insects, Herbicide- Crop Biotech Update (November 9, 2022) | Crop Biotech Update - ISAAA.org

isaaa.org

Agricultural biotechnology companies may charge royalties for:

Bt cotton technology.

Herbicide-resistant crops.

Genetically modified seeds.

Drought-resistant genetic traits.

Disease-resistant plant varieties.

A common commercial model involves a technology fee paid by seed manufacturers, sometimes calculated per seed packet or according to sales.

However, Indian law requires consideration of plant-variety protection, patent exclusions and applicable seed-price or trait-value regulations.

B. Gene therapy inventions

Viral Vector Manufacturing Services | Gene Therapies | AGC Biologics

agcbio.com

Gene therapy royalties may involve several patent owners, including:

Vector technology developers.

Gene-editing platform owners.

Delivery-system inventors.

Therapeutic gene developers.

Manufacturing-process patent holders.

A royalty-sharing arrangement may allocate revenue among different patent owners according to their respective contributions.

C. CRISPR gene-editing inventions

CRISPR-Cas9: Transformations in Gene Editing | AmBioTech

americanbiotechnologylaboratory.com

CRISPR-related licensing can involve separate rights over:

Cas proteins.

Guide RNA technologies.

Delivery mechanisms.

Editing methods.

Therapeutic applications.

Particular engineered cell products.

A company commercialising a CRISPR-based therapy may therefore require multiple licences.

This creates the possibility of royalty stacking, where multiple patent owners demand separate payments for technologies incorporated into one product.

D. Genetic diagnostic inventions

TTCRC - TATA TRANSLATIONAL CANCER RESEARCH CENTRE

ttcrc.org

Genetic diagnostic licensing may involve:

Diagnostic methods.

Sequencing technologies.

Specialised laboratory techniques.

Bioinformatics methods.

Genetically engineered testing materials.

The Myriad Genetics judgment is particularly relevant because it distinguishes patentable technical inventions from naturally occurring genetic information.

8. Royalty Stacking and Multiple Patent Ownership

Royalty stacking occurs when a single biotechnology product requires licences from several patent owners, each demanding a separate royalty.

For example, a gene therapy product might require:

A licence for the genetic construct.

A licence for the viral delivery vector.

A licence for the editing technology.

A licence for the manufacturing process.

A licence for a specialised diagnostic method.

If every patent owner demands a substantial percentage of product revenue, the cumulative royalty burden may make commercialisation financially impractical.

Possible legal solutions include:

Cross-licensing agreements.

Patent pools.

Royalty caps.

Proportionate royalty-sharing.

Joint licensing arrangements.

Negotiated sublicensing.

Competition-law scrutiny of restrictive licensing practices.

The parties should also distinguish between genuine independent patent rights and overlapping or invalid patent claims.

9. International Legal Framework

A. TRIPS Agreement

The Agreement on Trade-Related Aspects of Intellectual Property Rights provides the international framework for patent protection.

Important provisions include:

Article 27: Patentable subject matter and exclusions.

Article 28: Rights conferred by patents.

Article 30: Limited exceptions to patent rights.

Article 31: Other use without authorisation of the right holder.

Article 31bis: Certain compulsory licensing arrangements for pharmaceutical exports.

These provisions establish a balance between exclusive patent rights and public-interest safeguards.

B. Convention on Biological Diversity

The Convention on Biological Diversity recognises sovereign rights over biological resources and addresses access and benefit-sharing.

Its provisions are relevant when genetic inventions are developed using biological resources originating from countries or communities subject to access and benefit-sharing requirements.

C. Nagoya Protocol

The Nagoya Protocol provides an international framework for access to genetic resources and fair and equitable sharing of benefits arising from their utilisation.

It is important to distinguish these benefit-sharing obligations from private patent royalties.

For example, a company may have to pay:

Patent royalties to a biotechnology patent owner.

Contractual payments to a research institution.

Statutory benefit-sharing payments under applicable biodiversity legislation.

These obligations can coexist.

10. Important Contractual Safeguards in Genetic-Invention Licensing

A properly drafted genetic technology licensing agreement should contain the following clauses.

1. Ownership clause: Identifies the actual owner of the patent and any jointly developed genetic invention.

2. Royalty calculation clause: Specifies whether royalties are calculated on gross revenue, net sales, units manufactured or sublicensing income.

3. Research-use clause: Clarifies whether non-commercial academic research is permitted without royalty payments.

4. Territory clause: Defines the geographical areas where the licensee may exploit the invention.

5. Patent validity clause: Specifies the consequences if the underlying patent is invalidated or revoked.

6. Audit clause: Allows verification of sales, production volumes and royalty calculations.

7. Sublicensing clause: Determines whether the licensee can authorise third parties to use the genetic invention.

8. Public-interest clause: Provides for compliance with compulsory licensing, public-health requirements and other applicable statutory obligations.

9. Benefit-sharing clause: Addresses obligations arising from the utilisation of biological resources and associated traditional knowledge.

10. Dispute-resolution clause: Specifies the applicable law, jurisdiction, arbitration mechanism and procedures for resolving royalty disputes.

11. Major Legal Challenges

Several challenges arise in establishing fair royalty structures for genetic inventions.

A. Patent ownership disputes

Genetic inventions may be developed through collaborative research involving universities, pharmaceutical companies and independent scientists. Determining ownership and royalty entitlement can become complicated.

B. Excessive royalty demands

A patent holder may demand royalties that make essential genetic medicines or agricultural technologies unaffordable.

C. Genetic-resource exploitation

Commercial companies may obtain substantial financial benefits from genetic resources without adequately recognising the interests of the communities and countries that provided those resources.

D. Royalty stacking

Multiple patent claims over one biotechnology product can create excessive cumulative licensing expenses.

E. Farmers' rights

Agricultural biotechnology licensing must consider statutory protections for farmers, including relevant provisions of the Protection of Plant Varieties and Farmers' Rights Act, 2001.

F. Research exemptions

Licensing arrangements must distinguish between commercial exploitation and legally permitted experimental or research activities.

G. Cross-border licensing conflicts

A patent may be protected in one country but not another. Consequently, royalty obligations, patent validity and licensing restrictions may differ between jurisdictions.

12. Recommendations for a Fair Royalty Framework

A balanced royalty framework should incorporate the following principles:

Scientific contribution: Royalties should reflect genuine inventive contributions rather than merely ownership of naturally occurring genetic information.

Proportional remuneration: Payments should reflect the commercial value and technical contribution of the licensed invention.

Public accessibility: Essential genetic medicines and agricultural technologies should remain reasonably accessible.

Transparent accounting: Licensing agreements should provide clear royalty calculations and audit mechanisms.

Protection against monopoly abuse: Competition law should address unfair licensing conditions and exclusionary practices.

Equitable benefit-sharing: Communities and countries providing biological resources should receive applicable benefits.

Research protection: Legitimate scientific research should not be unnecessarily restricted through excessive licensing conditions.

International cooperation: Cross-border genetic technology licences should respect national patent laws and biodiversity obligations.

13. Conclusion

Royalty structures for genetic inventions represent an important intersection of patent law, biotechnology regulation, commercial contracts, competition law and biodiversity governance.

The decisions in Monsanto Technology LLC v. Nuziveedu Seeds Ltd., Association for Molecular Pathology v. Myriad Genetics, Bowman v. Monsanto and Monsanto Canada Inc. v. Schmeiser demonstrate that genetic technology licensing involves questions of patent eligibility, ownership, reproduction, commercial exploitation and financial compensation.

Indian law, particularly Sections 48, 83, 84 and 90 of the Patents Act, 1970, seeks to balance patent-holder remuneration with public accessibility and technological development.

Ultimately, a fair royalty structure should reward genuine innovation without allowing exclusive genetic technology rights to become instruments of unreasonable commercial control.

14. Quick Revision: Important Case Laws

Research note: The US and Canadian judgments are comparative authorities, not binding precedents in India. The Monsanto–Nuziveedu Supreme Court judgment also remitted the dispute rather than finally deciding the underlying patent-validity questions.

15. Important Legal References

Indian Patents Act, 1970 – Official Patent Legislation.

Section 90 – Terms and Conditions of Compulsory Licences.

Section 84 – Compulsory Licensing.

Supreme Court Judgment – Monsanto v. Nuziveedu.

US Supreme Court Judgment – Bowman v. Monsanto.

WIPO Case Summary – Monsanto v. Nuziveedu.